Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Literals

• bibo:eissn
  • 1532-6535
• dcterms:contributor
• bibo:doi
  • 10.1002/cpt.70071
• ou:eid
  • 2-s2.0-105016631276
• dcterms:creator
  • Eadon M.T.
• fabio:hasPublicationYear
  • 2025
• vivo:identifier
  • 2025-7026
• bibo:issn
  • 0009-9236
• dcterms:publisher
  • Clinical Pharmacology and Therapeutics
• ou:tipoPublicacion
  • Article
• dcterms:title
  • Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
• vcard:url
  • https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016631276&origin=inward
• ou:urlScopus
  • https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016631276&origin=inward
• ou:vecesCitado
  • 0

Typed Literals

• ou:openaccess
  • True (xsd:boolean)

Relations

• ou:publicadaEnRevista
  • CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Clinical Pharmacology and Therapeutics

Inverse Relations

• Has related: ou:tienePublicacion
  • JOSÉ AUGUSTO GARCÍA-AGÚNDEZ PÉREZ-COCA